Cormorant Asset Management MBX Position
Active9-Fund ConvergenceCormorant Asset Management trimmed their position in MBX Biosciences, Inc. (MBX) in Q4 2025, holding $35.3M worth of shares across 1,120,000 shares.
The position was first reported in Q3 2024 and has been tracked across 6 quarterly 13F filings.
MBX is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for 400 µg of MBX 2109 once-weekly by subcutaneous injection in 406 days (May 27, 2027), making the timing of Cormorant's position particularly relevant.
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Full company profile →Short Interest
9.7%
5.0 days to cover
Cormorant Asset Management MBX Position History
Frequently Asked Questions
Does Cormorant Asset Management own MBX?
Yes. As of Q4 2025, Cormorant Asset Management holds 1,120,000 shares of MBX Biosciences, Inc. (MBX) valued at $35.3M. This data comes from their SEC 13F filing.
How many hedge funds own MBX?
9 specialist biotech hedge funds currently hold MBX, including OrbiMed Advisors, Deep Track Capital, EcoR1 Capital and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Cormorant Asset Management first buy MBX?
Cormorant Asset Management's position in MBX was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Cormorant Asset Management's MBX position increasing or decreasing?
Cormorant Asset Management trimmed their MBX position in the most recent quarter, reducing by 105,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
MBXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Cormorant Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →